Is Caris Life Sciences, Inc. (CAI) a Buy, Sell, or Hold?
NASDAQ : CAI
Caris Life Sciences, Inc.
$15.59 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 3.16M
- Market Capitalization
- $4.41B
- P/E Ratio
- -10.02
- Dividend Yield
- 0.00%
- Price Target
- $23.50
- Year High
- $42.50
- Year Low
- $14.19
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.05
Company Overview
NASDAQ
David Dean Halbert
Biotechnology
Healthcare
CAI
1846
US
USD
Liquidity Metrics
0.73
7.05
7.05
5.71
0.00
Sales & Valuation
$812.03M
4.86
7.42
35.70
0.44
Profitability
-$1.9
-$537.96M
3.75%
3.73%
6.47%
2.92%
P/E Metrics
-10.02
0.04
0.04
Analyst Price Target & Rating
$23.50
$32.00
$21.00
2/5
7 Analysts
-33.66%
Financial Health Scores
3.56
7/9
$870.28M
$1.16B
$568.9M
$90.73M
Key Metrics (TTM)
$4.02B
4.43
36.07
7.05
6.47%
14.09%
0.77%
2.80%
$2.38
-53 days
Company Executives
| Name | Title |
|---|---|
| Jim Abraham | Senior VP & Chief Innovation Officer |
| Valeriy Domenyuk | Senior Vice President & Chief Technology Officer |
| Brian J. Brille | Executive Vice Chairman & Executive Vice President |
| Luke Power | Senior Vice President, Chief Financial Officer & Chief Accounting Officer |
| Narendra Chokshi | Senior Vice President of Corporate Development |
| Ginger Appleberry | Senior Vice President, Deputy General Counsel & Chief Compliance Officer |
| Stephanie Thomas | Executive VP & Chief of Staff at Office of the CEO |
| Jeremy O'Brien | Senior Vice President of Human Resources |
| Milan Radovich | Senior Vice President & Chief Scientific Officer |
| Jon Mark Harmon | Senior Vice President & Chief Operations Officer |
| David Dean Halbert | Chairman, Chief Executive Officer & Founder |
| David Spetzler | President |
| J. Russel Denton | Senior Vice President, General Counsel & Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Caris Life Sciences, Inc. (NASDAQ:CAI) Stock
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Establishe ... d in 2008, the company maintains its corporate headquarters in Irving, Texas.
Caris Life Sciences: Disrupting Cancer Screening And Therapy Selection
2026-07-21 05:29:37
Caris Life Sciences is rated a 'Buy' at ~$16.5, with a blended fair value estimate of $22.3, implying ~35% upside, and 23%-26% 2026 estimated revenue growth. CAI's proprietary WES/WTS/WGS technology and massive data advantage underpin its leadership in oncology diagnostics and pharma R&D services. Short-term signals are net positive: insider buying, a $100M share repurchase program, and a bullish put-call ratio against a downward technical trend.
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-16 08:30:00
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m.
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
2026-07-14 08:30:00
IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision oncology for this disease.
2026-07-01 08:30:00
Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithmsdelivers superior performance to existing cancer detection technologies IRVING, Texas, July 1, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the commercial launch of Caris Detect™, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Caris Detect is engineered to push the boundaries of what is possible in early cancer detection.
2026-06-24 09:07:00
ALLENTOWN, Pa., June 24, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, was awarded a statewide contract with the Virginia Information Technologies Agency (VITA) to provide Security Operations Center (SOC) services to local government entities across the Commonwealth.
CAI Named to Newsweek's America's Greatest Workplaces in Tech 2026
2026-06-17 09:06:00
ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it has been named to Newsweek's America's Greatest Workplaces in Tech 2026 list.
Caris Life Sciences Announces Dual Listing on NYSE Texas
2026-06-16 08:30:00
IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets. Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market.
Caris Life Sciences: The Discount To Peers Looks Hard To Ignore
2026-06-12 07:57:50
Caris Life Sciences is rated a buy, combining 79% Q1 2026 revenue growth, 65%+ gross margins, and positive free cash flow. CAI's genomic database of over one million cases underpins future products like Caris Detect, offering a potential competitive edge. At 5x EV/Sales, CAI trades at a discount to peers despite superior growth and profitability, further supported by a $100M buyback.
Frequently Asked Questions
-
What is the current Caris Life Sciences, Inc. (CAI) stock price?
-
Caris Life Sciences, Inc.(NASDAQ:CAI) stock price is $15.59 in the last trading session. During the trading session, CAI stock reached the peak price of $42.5 while $14.19 was the lowest point it dropped to. The percentage change in CAI stock occurred in the recent session was 0.0% while the dollar amount for the price change in CAI stock was $0.
-
CAI's industry and sector of operation?
-
The NASDAQ listed CAI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CAI?
-
Jim Abraham | Senior VP & Chief Innovation Officer
Valeriy Domenyuk | Senior Vice President & Chief Technology Officer
Brian J. Brille | Executive Vice Chairman & Executive Vice President
Luke Power | Senior Vice President, Chief Financial Officer & Chief Accounting Officer
Narendra Chokshi | Senior Vice President of Corporate Development -
How many employees does CAI have?
-
Number of CAI employees currently stands at 1846. CAI operates from 750 West John Carpenter Freeway, Irving, TX 75039, US.
-
Link for CAI official website?
-
Official Website of CAI is: https://www.carislifesciences.com
-
How do I contact CAI?
-
CAI could be contacted at phone #866 771 8946 and can also be accessed through its website. CAI operates from 750 West John Carpenter Freeway, Irving, TX 75039, US.
-
How many shares of CAI are traded daily?
-
The average number of CAI shares traded daily for last 3 months was 3.16M.
-
What is the market cap of CAI currently?
-
The market value of CAI currently stands at $4.41B with its latest stock price at $15.59